Literature DB >> 25447970

The addiction-related gene ANKK1 in Parkinsonian patients with impulse control disorder.

Janet Hoenicka1, Pedro J García-Ruiz, Guillermo Ponce, Antonio Herranz, Dolores Martínez-Rubio, Estela Pérez-Santamarina, Francesc Palau.   

Abstract

Impulse control disorders (ICDs) comprise a wide spectrum of abnormal behaviors frequently found in patients with Parkinson's disease (PD) receiving antiparkinsonian treatment. Some ICDs share several essential features with substance use disorders. In this work, we have studied the addiction-related gene ankyrin repeat and kinase domain containing I (ANKK1) in a sample of PD patients involved in a multicenter study on ICD. We carried out the TaqIA ANKK1 single-nucleotide polymorphism (SNP) genotyping in PD patients. Clinical assessment of ICD was performed using the Questionnaire for impulsive-compulsive disorders in PD. We found no association between TaqIA SNP and ICD in PD patients (p = 0.565). However, when PD patients were grouped according the diagnosis of any ICD with a potentially addictive reinforcement (ICDARs), A1- TaqIA genotype showed significant association (p = 0.036). No association was found for the presence of punding in PD patients (p = 0.289). A logistic regression analysis confirmed the independent effect of the A1- genotype upon ICDARs (OR 8.76, 95 % CI 1.3-57.8, Wald = 5.805, p = 0.024). The TaqIA genotype A1- is associated to ICDAR in our sample and it may differentiate two types of disorders which are part of the ICD definition in PD patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25447970     DOI: 10.1007/s12640-014-9504-x

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  20 in total

1.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.

Authors:  Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang
Journal:  Arch Neurol       Date:  2010-05

2.  Psychiatry. Behavioral addictions debut in proposed DSM-V.

Authors:  Constance Holden
Journal:  Science       Date:  2010-02-19       Impact factor: 47.728

3.  Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability.

Authors:  Kimberly Papay; Eugenia Mamikonyan; Andrew D Siderowf; John E Duda; Kelly E Lyons; Rajesh Pahwa; Erika D Driver-Dunckley; Charles H Adler; Daniel Weintraub
Journal:  Parkinsonism Relat Disord       Date:  2010-12-24       Impact factor: 4.891

Review 4.  Reward deficiency syndrome: genetic aspects of behavioral disorders.

Authors:  D E Comings; K Blum
Journal:  Prog Brain Res       Date:  2000       Impact factor: 2.453

Review 5.  Genetic susceptibility of impulse control and related behavior in Parkinson's disease.

Authors:  Young Eun Kim; Beom S Jeon
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

6.  The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine.

Authors:  E Garrido; T Palomo; G Ponce; I García-Consuegra; M A Jiménez-Arriero; J Hoenicka
Journal:  Neurotox Res       Date:  2010-09-16       Impact factor: 3.911

7.  Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease.

Authors:  Valerie Voon; Teri Thomsen; Janis M Miyasaki; Minella de Souza; Ariel Shafro; Susan H Fox; Sarah Duff-Canning; Anthony E Lang; Mateusz Zurowski
Journal:  Arch Neurol       Date:  2007-02

8.  DRD2 and ANKK1 genotype in alcohol-dependent patients with psychopathic traits: association and interaction study.

Authors:  G Ponce; J Hoenicka; M A Jiménez-Arriero; R Rodríguez-Jiménez; M Aragüés; N Martín-Suñé; E Huertas; T Palomo
Journal:  Br J Psychiatry       Date:  2008-08       Impact factor: 9.319

9.  Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome.

Authors:  Andrew H Evans; Regina Katzenschlager; Dominic Paviour; John D O'Sullivan; Silke Appel; Andrew D Lawrence; Andrew J Lees
Journal:  Mov Disord       Date:  2004-04       Impact factor: 10.338

10.  Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease.

Authors:  Daniel Weintraub; Staci Hoops; Judy A Shea; Kelly E Lyons; Rajesh Pahwa; Erika D Driver-Dunckley; Charles H Adler; Marc N Potenza; Janis Miyasaki; Andrew D Siderowf; John E Duda; Howard I Hurtig; Amy Colcher; Stacy S Horn; Matthew B Stern; Valerie Voon
Journal:  Mov Disord       Date:  2009-07-30       Impact factor: 10.338

View more
  4 in total

1.  Dysregulation of Hypothalamic Gene Expression and the Oxytocinergic System by Soybean Oil Diets in Male Mice.

Authors:  Poonamjot Deol; Elena Kozlova; Matthew Valdez; Catherine Ho; Ei-Wen Yang; Holly Richardson; Gwendolyn Gonzalez; Edward Truong; Jack Reid; Joseph Valdez; Jonathan R Deans; Jose Martinez-Lomeli; Jane R Evans; Tao Jiang; Frances M Sladek; Margarita C Curras-Collazo
Journal:  Endocrinology       Date:  2020-02-01       Impact factor: 4.736

2.  Regulatory rare variants of the dopaminergic gene ANKK1 as potential risk factors for Parkinson's disease.

Authors:  Francesc Palau; Janet Hoenicka; Estela Pérez-Santamarina; Pedro García-Ruiz; Dolores Martínez-Rubio; Mario Ezquerra; Irene Pla-Navarro; Jorge Puente; María José Martí
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.996

Review 3.  Impulse Control Disorders in Parkinson's Disease: From Bench to Bedside.

Authors:  Andrea Augustine; Catharine A Winstanley; Vaishnav Krishnan
Journal:  Front Neurosci       Date:  2021-03-12       Impact factor: 4.677

4.  Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson's Disease.

Authors:  Aleksander H Erga; Ingvild Dalen; Anastasia Ushakova; Janete Chung; Charalampos Tzoulis; Ole Bjørn Tysnes; Guido Alves; Kenn Freddy Pedersen; Jodi Maple-Grødem
Journal:  Front Neurol       Date:  2018-02-28       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.